The Scheme seeks to provide returns that, before expenses, correspond to the total return of theunderlying index (Nifty Healthcare Index), subject to tracking error.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| ETFs | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -6.38% | -4.46% | 7.52% | 9.13% | 4.92% | 3.21% | N/A | N/A | N/A | N/A | 12.66% |
| Category returns | -2.99% | -4.52% | -3.02% | -5.03% | -4.77% | -2.03% | 9% | 10.98% | 7.45% | 11.5% | N/A |
| Absolute returns | -6.38% | -4.46% | 7.52% | 9.13% | 4.92% | 6.52% | N/A | N/A | N/A | N/A | 38.22% |
| Rank within category | 248/268 | 94/252 | 10/241 | 15/228 | 18/207 | 29/162 | N/A | N/A | N/A | N/A | N/A |
| ETFs | 2024 | 2025 | 2026 |
|---|---|---|---|
| Yearly returns | N/A | -1.71% | 6.59% |
| Q1 returns | N/A | -8.37% | -2.86% |
| Q2 returns | 4.26% | 5.78% | 13.69% |
| Q3 returns | 17.64% | -2.02% | 0.13% |
| Q4 returns | 1.31% | 3.49% | -3.6% |
| Alpha | -0.0175808 |
| Beta | 0.9987 |
| Sharpe Ratio | 0.158419 |
| Sortino Ratio | 0.319527 |
| R-Squared | 0.9969 |
| Tracking Error | 0.0147 |
| Downside Risk | 16.9161 |
| Std. Deviation (Annualised) | 13.3765 |
| ETFs | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | -7.16% | -4.01% | 10.11% | 12.75% | 6.7% | 19.48% | N/A | N/A | 19.41% | 44.40 | 0.36 | 0.30 | Very High |
| Nippon India Nifty Pharma ETF | -4.12% | -0.09% | 14.11% | 16.17% | 15.52% | 19.28% | 12.79% | N/A | 12.07% | 1,736.44 | 0.23 | 0.30 | Very High |
| Motilal Oswal BSE Enhanced Value ETF | -3.37% | -6.03% | -9.38% | -9.5% | -0.01% | 18.7% | N/A | N/A | 26.28% | 146.61 | 0.43 | 0.20 | Very High |
| DSP Nifty PSU Bank ETF | -0.29% | -1.08% | -5.84% | -7.11% | 9.24% | 18.66% | N/A | N/A | 20.49% | 1,434.17 | 0.16 | 0.15 | Very High |
| ICICI Prudential Nifty PSU Bank ETF | -0.32% | -1.15% | -6.01% | -7.33% | 8.91% | 18.53% | N/A | N/A | 26.2% | 118.61 | 0.41 | 0.15 | Very High |
| Nippon India ETF Nifty PSU Bank BeES | -0.32% | -1.17% | -6.04% | -7.39% | 8.81% | 18.35% | 25.56% | 10.01% | 6.93% | 3,932.00 | 0.51 | 0.14 | Very High |
| Kotak Nifty PSU Bank ETF | -0.32% | -1.17% | -6.06% | -7.4% | 8.79% | 18.33% | 25.56% | 9.94% | 6.36% | 2,490.74 | 0.51 | 0.14 | Very High |
| Aditya Birla Sun Life Nifty Healthcare ETF | -6.38% | -4.45% | 7.53% | 9.15% | 4.95% | 18.01% | 0% | N/A | 12.85% | 74.67 | 0.20 | 0.27 | Very High |
| ICICI Prudential Nifty Healthcare ETF | -6.38% | -4.44% | 7.56% | 9.19% | 5% | 17.87% | 12.38% | N/A | 12.86% | 231.43 | 0.16 | 0.27 | Very High |
| DSP Nifty Healthcare ETF Current | -6.38% | -4.46% | 7.52% | 9.13% | 4.92% | N/A | N/A | N/A | 12.66% | 17.06 | 0.21 | 0.16 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 16.99% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 10.43% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 7.42% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.81% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.69% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.64% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.24% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 6.11% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.36% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.08% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.54% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.11% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.75% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.54% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.51% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.36% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.28% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.04% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 1.76% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.26% |
| TREPS / Reverse Repo Investments | Cash & Cash Equivalents and Net Assets | 0.10% | |
| Net Receivables/Payables | Cash & Cash Equivalents and Net Assets | -0.03% | |
| Total | 100.00% | ||
Anil has been working with the DSP Group since 2003. He is currently the Head of Passive Investments & Products, managing a range of ETFs and Index Funds across asset classes. Previously, he served as the CEO & Chief Investment Officer at DSP BlackRock Pension Fund Managers. Earlier in his career at DSP, he led the Risk and Quantitative Analysis team, providing quantitative research inputs and buy-side credit research on companies across various sectors. Prior to joining DSP, Anil worked at IL&FS Asset Management Company and at S.R. Batliboi, a member firm of EY. Anil has been a volunteer with the CFA Society India for more than a decade and has served as Vice Chairman on the board.
Diipesh has a total work experience of over 20 years. He has been working with DSP since September 2019 as a Dealer for ETF and Passive Investments. He is now also the Fund Manager of various schemes of DSP Mutual Fund. Diipesh has also worked with JM Financial Institutional Broking Ltd., Centrum Broking Lt.d, IDFC Securities Ltd., and Kotak Securities Ltd. in Institutional Equity Sales Trading. He is a Chartered Accountant (ICAI, India) and also holds a Bachelor of Commerce degree.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
